Delivery Order SPE2DB20D2001-SPE2DB25FPMZH
- Not listed
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a contract ceiling value of $27,331.63. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The order has an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Gemtesa 75 mg tablets (90-count) under a firm fixed-price contract valued at $22,758.48. The order was competitively awarded with no set-aside designation and carries an ultimate completion date of June 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a $22,655.56 delivery order to AmerisourceBergen Drug Corp on June 10, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of June 11, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's broader pharmaceutical supply relationship with the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on August 18, 2025, with a ceiling value of $10,325.86. The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This delivery order represents a single transaction...
- The Defense Logistics Agency awarded a $12,673.62 delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on May 30, 2025, with an ultimate completion date of June 2, 2025. This firm fixed-price contract, which involves no set-aside designation, represents a competitively awarded delivery order under the company's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The work will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $4,606.47. This delivery order represents a firm fixed-price, non-set-aside contract to be completed by September 15, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award is issued under the company's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) with a ceiling value of $1,722.87. This firm fixed-price delivery order, awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a non-competitive award under an existing contract vehicle. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, which serves as AmerisourceBergen's corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count) with a ceiling value of $3,100.69. The contract was competitively awarded on August 29, 2025, with an ultimate completion date of September 2, 2025, and utilizes firm fixed pricing. Performance will take place at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order carries no set-aside designation, reflecting open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed price contract valued at $43,743.38. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 17, 2025. The contract is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as...
- The Defense Logistics Agency awarded a delivery order valued at $1,350.51 to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Gemtesa 75 mg tablets (90-count). This competitively awarded, firm fixed-price delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. The contract utilizes no set-aside designation, reflecting the vendor's demonstrated capability to compete in...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB25FPMZHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Gemtesa 75 mg tablets in a quantity of 90 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $12,795.74 and is scheduled for ultimate completion on June 20, 2025. The contract specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award carries no set-aside designation, indicating it was competed among all eligible vendors in the open market. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.99 million through December 2026. As a major pharmaceutical distributor and critical federal medical supply vendor, AmerisourceBergen maintains an extensive portfolio of pharmaceutical products and medical supplies supporting military and veteran healthcare systems. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains to support Defense Health Agency and other federal healthcare customers worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.8k | 6/18/25 |